Bavarian Nordic A/S announced a licensing and manufacturing agreement with Serum Institute of India Pvt. Ltd. (SII)’s MVA-BN mpox vaccine.
As part of this collaboration, the two companies will transfer technology from MVA-BN’s existing manufacturing process to SII. This will enable SII to supply the vaccine to the Indian market, where it has exclusive sales and distribution rights.
Additionally, subject to the necessary regulatory approvals, SII will undertake contract manufacturing of MVA-BN for the Nordic state of Bavaria, thereby expanding global manufacturing capacity and ensuring sufficient supply in the event of an mpox outbreak. .
The agreement is structured on a profit-sharing model with no upfront or milestone payments. SII will be responsible for securing and maintaining regulatory approval for the vaccine in India, and costs associated with technology transfer will be borne by both parties respectively.
Bavarian Nordic continues to explore further partnerships with African manufacturers to promote equitable access to MVA-BN around the world.
Adar Poonawalla, CEO of Serum Institute of India, said: “Our mission has always been to provide high-quality, affordable vaccines to the world. The outbreak highlights the critical need for a rapid and coordinated response to the Bavarian MVA-BN mpox vaccine. Our partnership with Nordic reflects our shared commitment to protecting millions of people at risk, leveraging our manufacturing and rapid response capabilities to respond to outbreaks. We aim to strengthen preparedness, expand access to life-saving vaccines, protect vulnerable populations and reduce the global burden of MPOX.”
Paul Chaplin, President and CEO of Bavarian Nordic, said: “We are pleased to enter into a licensing and manufacturing agreement for MVA-BN as MPX Vaccine. This represents a major step forward in our efforts to expand access to vaccines for all people. ”Currently, the production capacity is Although there are no power constraints, scaling up global manufacturing is an important step to ensure continued and equitable access to vaccines for all countries, and is the world’s largest vaccine manufacturer by volume. We are pleased to establish a cooperative relationship with SII. We continue to work with partners around the world to explore further opportunities for local manufacturing to further support vaccine supply. ”
====
